New Horizons in the Management of Metastatic Pancreatic Cancer
Speakers: Eileen M. O'Reilly, MD, Attending Physician, Member
Andrea Wang-Gillam, MD, PhD, Associate Professor, Department of Medicine
Duration: 60 minutes
Presented on: February 15, 2017
Eileen M. O'Reilly, MD
Eileen M. O'Reilly, MD
Attending Physician, MemberEileen M. O’Reilly, MD, is associate director for clinical research for the David M. Rubenstein Center for Pancreatic Cancer Research, attending physician and member at Memorial Sloan-Kettering Cancer Center (MSKCC), and professor of medicine at Weill Medical College of Cornell University in New York. Her research initiatives include integrating molecular and genetic-based therapies for the treatment of pancreatic cancer, along with developing adjuvant and neoadjuvant therapies and identifying biomarkers that may be used to select therapy. Dr O’Reilly is the principal investigator of multiple phase I, II and III trials in pancreatic cancer, and has authored/co-authored multiple articles, editorials, and book chapters. She received her MD at Trinity College (Dublin University) in Ireland.
Andrea Wang-Gillam, MD, PhD
Andrea Wang-Gillam, MD, PhD
Associate Professor, Department of MedicineAndrea Wang-Gillam received MD and PhD from University of Arkansas for Medical Science (UAMS). She completed the intern year at Cleveland Clinic Foundation, OH, and internal medicine residency and hematology/oncology fellowship training in UAMS, Dr. Wang-Gillam joined the Division of Oncology at Washington University in St. Louis in 2007, and she is an associate professor and clinical director of the Gastrointestinal Oncology Program there. Dr. Wang-Gillam’s research interest is in the area of novel therapy development in pancreatic cancer, and she is a principal investigator for multiple clinical studies in pancreatic cancer.
New Horizons In the Management of Metastatic Pancreatic Cancer
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC
ACKNOWLEDGEMENT This activity is supported by an independent educational grant from Merrimack Pharmaceuticals.
ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENTS Live Activity The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Enduring Material The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DATE OF RELEASE/EXPIRATION Live Activity Wednesday, February 15, 2017 from 1:00 – 2:00PM ET Enduring Material The enduring material will be available from February 15, 2017 to August 15, 2017
LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to:
• Examine the safety and efficacy data of emerging and available treatment options for patients with metastatic pancreatic cancer • Evaluate and select optimal treatment algorithms for patients with metastatic pancreatic cancer
TARGET AUDIENCE This activity is intended for medical oncologists, gastroenterologists, and other health care professionals (primary care physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved or interested in the management of patients with pancreatic cancer.
ESTIMATED TIME TO COMPLETE This activity consists of one session, which should take approximately 1 hour to complete.
METHOD OF PARTICIPATION There are no fees to participate in this activity. To participate in the activity, go to www.omedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
DISCLOSURE OF CONFLICTS OF INTEREST Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Eileen M. O'Reilly, MD Professor of Medicine Weill Cornell Medical College
Consulting Fees: Aduro Biotech, Agios, Array, Aslan, Astellas Pharma US, Bayer, Blueprint, Boston Scientific, BMS, CASI, Celgene, Celsion, Delcath, Eisai, EMD Serono, Gilead, Halozyme, Integragen, Ipsen, Jansen, Merck, Merrimack, Momenta, New B Innovation, NewLink Genetics, Onxeo, Opsona, Pfizer, Roche, Sanofi-Aventis, Servier, Silenseed, Sillajen, Sirtex, Vaxxim, Vicus Therapeutics, Westhaven Contracted Research: Amgen, Astra Zeneca, Bayer, BMS, CASI, Celgene, Chugai, Exelixis, Genentech Inc., Incyte, Lilly, Mabvax, Medimmune, Momenta, Myriad Genetics, OncoMed Pharmaceuticals Polaris Pharmaceuticals, Roche, Vicus Therapeutics
Andrea Wang–Gillam, MD, PhD Associate Professor, Department of Medicine Washington University School of Medicine
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner Reported Financial Relationship Hamsa Jaganathan, PhD Medical Director PlatformQ Health Education, LLC None
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.
The following PlatformQ Health Education, LLC planner, Elizabeth del Nido, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable): This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
CONTACT INFORMATION Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.